valiloxybate (XW10172 MR) / XWPharma, Avadel - LARVOL DELTA

Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd (GlobeNewswire) - "Under the terms of the agreement, XWPharma grants Avadel an exclusive global license to develop, manufacture and commercialize valiloxybate worldwide, excluding mainland China, Hong Kong, and Macau. XWPharma will receive an upfront payment of $20 million from Avadel....Avadel expects to advance its valiloxybate formulation into an initial PK study in the fourth quarter of 2025, followed by a pivotal PK trial in the second half of 2026."

Licensing / partnership • New trial • Insomnia • Narcolepsy • Sleep Disorder

Valiloxybate (XW10172 MR) Efficacy and Safety Parkinson's Disease Study (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: XWPharma | N=70 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • CNS Disorders • Excessive Daytime Sleepiness • Movement Disorders • Parkinson's Disease • Sleep Disorder